Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.
Ionis Pharmaceuticals’ revenues from its Research and Development segment under the collaborative agreements totaled $61.0 million during the second quarter, compared to $88.0 million during the second quarter of 2017.
The company’s Commercial Revenues segment reported revenues of $57.0 million during the second quarter, compared to $24.0 million during the second quarter of 2017.
Key drugs portfolio
Currently, the products that have been developed by Ionis Pharmaceuticals include the following drugs from its severe and rare disease franchise:
- Spinraza (nusinersen), a drug for patients with spinal muscular atrophy, is codeveloped in collaboration with Biogen (BIIB). Biogen holds the development, manufacturing, and commercializing licenses for Spinraza.
- The Kynamro injection is an FDA-approved treatment for homozygous familial hypercholesterolemia. The injection is also approved in several other countries. The worldwide development and commercialization rights are held by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
- Tegsedi (inotersen), or Ionis-TTRRx, is a drug for the treatment of patients with transthyretin amyloidosis. Tegsedi (inotersen) is approved in the European Union.
Ionis’s late-stage pipeline includes Waylivra (volanesorsen). Waylivra is a drug under development for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy.
The First Trust NYSE Arca Biotechnology ETF (FBT) holds 3.5% of its total investments in Ionis Pharmaceuticals (IONS), 3.6% in Seattle Genetics (SGEN), 3.5% in Amgen (AMGN), and 3.3% in Celgene (CELG).